Skip to content

To Compare the Effect of Leech Therapy and Purgation Therapy in the Management of Atopic Eczema

A Randomised Controlled Trial to Compare the Effect of Jalaukavacharana and Virechana with Ichhabhedi Rasa in the Management of Vicharchika with Special Reference to Atopic Eczema

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/12/047825
Enrollment
40
Registered
2022-12-01
Start date
Unknown
Completion date
Unknown
Last updated
2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L209- Atopic dermatitis, unspecified

Interventions

None listed

Sponsors

Dr. POOJA PRATAP GIRI
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of age group between 16-65 years. 2. Lesions not more than 12cm in diameter. 3. Patients having cardinal symptoms like itching, erythema, blackish discoloration, discharge. 4. Patients who are fit for Jalaukavacharana36 and Virechana

Exclusion criteria

Exclusion criteria: 1. Lesions with secondary infection. 2. Patients on corticosteroids treatment. 3. Patients having systemic disorders, any drug reaction and allergic history. 4. Patients having uncontrolled diabetes.

Design outcomes

Primary

MeasureTime frame
Evaluation of effectiveness of Jalaukavacharana in Kandu, Daha, Pidaka, Ruja, Shyavata, Rukshata, Bahustrava, Raji of the subjects in comparison with Virechana with Ichhabhedi rasa in the management of atopic Eczema (Vicharchika).Timepoint: At the end of 31 days.

Secondary

MeasureTime frame
1. Assessment of severity of Atopic eczema on EASI scale. 2) Assessment of severity of Atopic eczema on the basis of serum cortisol levels.Timepoint: At the end of 31 days.

Countries

India

Contacts

Public ContactDr Pooja Pratap Giri

Shri Ayurved Mahavidyalaya, Nagpur

shantipushpa@gmail.com9822267964

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026